PHOSIMMUNE
PhosImmune is a clinical-stage biotechnology company developing therapeutic cancer vaccines. PhosImmune controls a library of unique, aberrantly phosphorylated tumor antigens (PTAs) that are directly implicated in metastasis, meeting a pressing need for high quality tumor antigens for use in new and more effective cancer vaccines.
PHOSIMMUNE
Industry:
Biotechnology Clinical Trials
Founded:
2012-01-01
Address:
Charlottesville, Virginia, United States
Country:
United States
Website Url:
http://www.phosimmune.com
Total Employee:
51+
Status:
Closed
Contact:
434-981-4995
Total Funding:
0
Technology used in webpage:
Google Font API Domain Not Resolving CloudFront Pound Sterling
Current Employees Featured
Donald Hunt President & Scientific Founder @ PhosImmune
President & Scientific Founder
Founder
Investors List
Virginia Venture Partners
Virginia Venture Partners investment in Venture Round - PhosImmune
More informations about "PhosImmune"
PhosImmune Company Profile 2025: Valuation, Investors
Information on acquisition, funding, cap tables, investors, and executives for PhosImmune. Use the PitchBook Platform to explore the full profile.See details»
PhosImmune - Products, Competitors, Financials, Employees, …
About PhosImmune PhosImmune is a cancer immunotherapy company that was founded to commercialize a library of phosphopeptide tumor targets (PTTs) discovered at the University …See details»
PhosImmune - Contacts, Employees, Board Members, Advisors
PhosImmune, a Charlottesville-based clinical-stage biotechnology companySee details»
PhosImmune - VentureRadar
Acquired/Merged "PhosImmune Inc. is developing cancer vaccines based on a class of aberrantly phosphorylated antigens that are directly involved in cellular transformation and/or metastasis. …See details»
Agenus Acquires PhosImmune for Up to $44.9M
Dec 24, 2015 Agenus said it has acquired PhosImmune for up to $44.9 million in cash and stock, in a deal the buyer said would give it the ability to speed up development of new cancer vaccines, other single ...See details»
QTsome | The WhiteOak Group, Inc.
Delivery of drug to the correct site of therapeutic action while minimizing off-target exposure is paramount to achieving safe and effective therapy. The WhiteOak Group, Inc. overcomes delivery challenges in complex diseases including …See details»
Agenus Acquires PhosImmune - Technology Networks
Jan 4, 2016 Agenus ,an immunotherapy company developing innovative treatments for cancer, has announced that it has acquired privately-held PhosImmune Inc., a company that has …See details»
Joseph L. Faber | Faber Daeufer & Itrato
Nov 1, 2020 Joe often serves as outside general counsel for venture-backed drug discovery and development companies. In addition, he functions as lead outside transactional counsel for emerging companies seeking strategic …See details»
Agenus - Funding, Financials, Valuation & Investors - Crunchbase
Agenus is registered under the ticker NASDAQ:AGEN . Their stock opened with $18.00 in its Feb 4, 2000 IPO. Agenus is funded by 5 investors. Ligand Pharmaceuticals and Incyte are the …See details»
Agenus Acquires PhosImmune, Adds Cancer Neoantigens - Nasdaq
Dec 28, 2015 Agenus' decision to acquire PhosImmune was a strategic move. The acquisition will help to accelerate the company's the ability to develop new cancer vaccines and other …See details»
PhosImmune - CB Insights
Explore {PhosImmune's key management people. Discover current leadership team members including founders, CEO, other executives and board directors.See details»
Agenus (AGEN) to Acquire PhosImmune in ~$45M Deal
Agenus Inc. (NASDAQ: AGEN) announced that it has acquired privately-held PhosImmune Inc., a company that has discovered an entirely new portfolio of cancer neoantigens. The acquisition …See details»
CSACI - Canadian Society of Allergy and Clinical Immunology
Feb 11, 2025 Canadian Society of Allergy and Clinical Immunology main page for news and information.See details»
Autoimmune Organizations - Global Autoimmune Institute
Discover leading autoimmune disease organizations. Find support, resources, and advocacy for autoimmune conditions.See details»
Microsoft Word - PhosImmune_PureMHC_PR 141021.docx
PhosImmune possesses technology for the identification of phosphorylated peptides displayed on the surfaces of tumor cells in association with HLA molecules. These phosphopeptide tumor …See details»
Thomas Haag Profile: Contact Information & Network | PitchBook
Information on current and former positions, network members and contacts for Thomas Haag. Use the PitchBook Platform to explore the full profile.See details»
Simmunome Inc.
Simmunome creates accurate, comprehensive in silico disease models using multi-omic data to de-risk drug development.See details»
Immune Deficiency Foundation
"Compromised: Life Without Immunity" takes you inside the rarely-seen world of primary immunodeficiency. Through six powerful stories, discover how strength, support, and medical …See details»
PhosImmune, Inc. - 药物管线_专利_临床试验_投融营收
关联 100 项与 PhosImmune, Inc. 相关的临床结果 登录后查看更多信息 0 项与 PhosImmune, Inc. 相关的专利（医药） 登录后查看更多信息 100 项与 PhosImmune, Inc. 相关的药物交易 登录 …See details»